View Author
Zuylen, L. van
( L. van Zuylen)
docetaxel patient r 101933 plasma paclitaxel study concentration cancer sam 486a pharmacokinetic blood level infusion cycle treatment 100 mg /m dose level combination p-glycoprotein sample toxicity phase fraction table 5- fu 5- fu /lv value grade disposition ratio metabolite analysis administration inhibitor agent sparreboom resistance treatment courses effect anticancer drugs human anticancer b.i.d metastatic colorectal cancer research compound multidrug resistance parameter function 125 mg /m cremophor el rotterdam cremophor plasma concentrations colorectal distribution elimination metabolism range fluorouracil erythrocyte tumor 200 mg b.i.d janssen research foundation neutropenia dose levels blood samples protein curve profile beijnen limit presence result course regimen excretion tissue 3- h period chemotherapy
4 Most Recent Publications
|
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer
(Article)
Zuylen, L. van Mueller, C. Choi, L. Bootle, D. Verweij, J. Ledermann, J.A. Bridgewater, J. Sparreboom, A. Eskens, F.A.L.M. Bruijn, P. de Sklenar, I. Planting, A.S.Th. |
2004-01-01
|
|
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
(Article)
Zuylen, L. van Sparreboom, A. Gaast, A. van der Burg, M.E.L. van der Beurden, V. van Bol, C.J. Woestenborghs, R. Palmer, P.A. Verweij, J. |
2000-01-01
|
|
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans
(Article)
Zuylen, L. van Verweij, J. Nooter, K. Brouwer, E. Stoter, G. Sparreboom, A. |
2000-01-01
|
|
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications
(Article)
Sparreboom, A. Zuylen, L. van Brouwer, E. Loos, W.J. Bruijn, P. de Gelderblom, A.J. Pillay, M. Nooter, K. Stoter, G. Verweij, J. |
1999-04-01
|
